STAINES-UPON-THAMES, United Kingdom and ROCKVILLE, Md., Dec.
26, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global
specialty pharmaceutical company, and Sucampo Pharmaceuticals, Inc.
(NASDAQ: SCMP), a global biopharmaceutical company, today announced
that they have entered into an agreement under which Mallinckrodt will acquire Sucampo, including its
commercial and development assets. The transaction was approved by
the Boards of Directors of both companies.
"Mallinckrodt's acquisition of
Sucampo is the latest milestone towards our vision of becoming an
innovation-driven specialty pharmaceutical growth company focused
on improving outcomes for patients with severe and critical
conditions," said Mark Trudeau,
Chief Executive Officer and President of Mallinckrodt. "The acquisition brings near-term
net sales and earnings accretion through AMITIZA and bolsters our
pipeline in rare diseases with VTS-270 and CPP-1X/sulindac. We look
forward to adding the Sucampo portfolio and welcoming members of
its team to Mallinckrodt."
"This transaction is a testament to the hard work and dedication
of Sucampo's employees. Together we have made extraordinary
progress in our mission to provide options for patients affected by
diseases with few or no current treatment options, and to their
caregivers and physicians. We believe that this transaction with
Mallinckrodt represents significant
value for shareholders," said Peter
Greenleaf, Chairman and Chief Executive Officer of
Sucampo. "With the addition of its significant resources and
expertise, we believe Mallinckrodt is a
natural partner to accelerate the development of our rare disease
assets in NPC and FAP, and to continue to provide AMITIZA for
patients suffering from constipation-related disorders."
Sucampo's Commercial Assets
AMITIZA®
(lubiprostone), a leading global product in the branded
constipation market, is approved by the U.S. Food and Drug
Administration (FDA) for treatment of chronic idiopathic
constipation (CIC) in adults, irritable bowel syndrome with
constipation (IBS-C) in women 18 years of age and older, and
opioid-induced constipation (OIC) in adult patients with chronic,
non-cancer pain, including patients with chronic pain related to
prior cancer or its treatment who do not require frequent opioid
dosage escalation. AMITIZA is a chloride channel activator which
increases fluid secretion and motility of the intestine,
facilitating passage of stool. The FDA is currently reviewing a
supplemental New Drug Application (sNDA) for AMITIZA in children 6
to 17 years of age with pediatric functional constipation (PFC).
The sNDA received a Priority Review designation and has a user
fee1 goal date of January 28,
2018.
Roughly 40 million patients in the U.S. suffer from some form of
chronic constipation. While the most common treatments include
over-the-counter laxatives, branded prescription drugs hold about
10% of the total chronic constipation market, resulting in
approximately 4.2 million prescriptions and annual growth of 10% to
15% 2. In 2016, net sales of branded products for
treatment of CIC, OIC and IBS-C were $1.6
billion3, with AMITIZA holding approximately 30%
of those net sales. Of the branded products currently marketed,
only AMITIZA is approved for three constipation indications in the
U.S. The drug is promoted through commercial agreements in the
U.S., the United Kingdom and
Switzerland (all through Takeda
Pharmaceutical Company Ltd.), and in Japan (Mylan N.V.). An Investigational New
Drug Application for the product has been accepted in China (Harbin Gloria Pharmaceuticals Co.,
Ltd.). Reported 2016 global net sales of AMITIZA equaled
$456 million. If approved for PFC in
the first quarter of 2018, AMITIZA would be the first and only
approved prescription therapy available to treat children with PFC,
a condition which affects approximately 18%4 of the
pediatric population.
RESCULA® (unoprostone isopropyl ophthalmic
solution) 0.15%, is indicated for ocular
hypertension and open-angle glaucoma, and marketed in Japan. Mallinckrodt will acquire global rights to the
product, with annual net sales of approximately $9 million.
Sucampo's Development Assets
VTS-270 is
in Phase 3 development for Niemann-Pick Type C (NPC). NPC is a
rare, neurodegenerative, and ultimately fatal disease that can
present at any age. NPC is caused by mutations in either the NPC1
or NPC2 genes, resulting in the disruption of the trafficking of
intracellular cholesterol, leading to intracellular lipid
accumulation in various tissues, including the brain, liver, and
spleen 5,6,7,8,9,10,11,12. NPC presents with neurologic
and visceral features that overlap with other diseases often
leading to a missed or delayed diagnosis. Neurodegenerative
presentation in NPC is a major driver of morbidity and
mortality13,14,15,16,17. On average, patients die 12.6
years from the onset of neurological symptoms18. There
are four main types of the disease – types A, B, C1 and C2; NPC
encompasses types C1 and C2, which represents 95% of
cases19 and causes accumulation of cholesterol and other
lipids in cells, resulting in severe neurological, systemic or
psychiatric disorders. Manifestations of the genetic disorder
typically occur in childhood5,6, with occasional late
onset, and average diagnosis at ten years of age20. NPC
is usually fatal, and the majority of cases lead to death before
age 205,6. Diagnosis is challenging due to the
variability of symptoms6, which could improve with
awareness created by a new treatment option. Worldwide estimated
prevalence for the rare disease is approximately 2,000 to 3,000
patients, with about 500 cases in the U.S.
alone21,22,23.
The FDA granted VTS-270 its Orphan Drug Designation, and the
resulting seven years' exclusivity would be applied upon approval
of the drug. The European Medicines Agency (EMA) also granted
VTS-270 Orphan Drug status. In addition, the FDA granted the
compound its Breakthrough Designation24, indicating the
drug is (1) intended to treat a serious or life-threatening disease
or condition alone or combined with one or more other drugs, and
(2) preliminary clinical evidence indicates it may demonstrate
substantial improvement over existing therapies on one or more
clinically significant endpoints. The Breakthrough Designation
status results in expedited review by the agency.
Additionally, since VTS-270 has been designated as a rare
pediatric disease treatment, it is expected – upon successful
completion of the VTS-270 Phase 3 trial and submission of the
regulatory filing and subsequent approval of the New Drug
Application (NDA) by the FDA – that the company would receive a
Priority Review Voucher, awarded by the agency to those sponsors
that meet certain criteria25. Once received, the voucher
could be redeemed by Mallinckrodt to
receive priority review of a subsequent separate product's
marketing application, or the company could choose to monetize the
voucher. If the company receives the voucher and chooses to
monetize it, a part of the proceeds would be shared with VTS-270's
former owner's (Vtesse Inc.) shareholders.
Results of the VTS-270 Phase 1/2a data showed the potential for
a disease modifying effect based on slowing of progression on
neurological, disease-specific outcomes measures and promising
clinical improvements in patients with NPC. Current therapeutic
approaches are palliative and show limited evidence of efficacy in
delaying disease progression 26 ,27. If
approved, VTS-270 will provide patients with a directly targeted
disease-modifying therapy. The Phase 3 trial is ongoing, with the
NDA filing currently expected in 2018, and approval anticipated in
2019. Mallinckrodt will acquire global
rights to the therapy. Peak net sales for the product, if approved,
are estimated at greater than $150
million.
CPP-1X/sulindac is in Phase 3 development for
Familial Adenomatous Polyposis (FAP) under a collaborative
agreement between Cancer Prevention Pharmaceuticals (CPP) and
Sucampo. FAP results from a genetic mutation leading to
uncontrolled growth of hundreds to thousands of polyps in the lower
digestive tract 28. Left untreated, there is almost a
100% lifetime risk of developing colorectal cancer 29.
The disease typically progresses without clear warning signs until
reaching advanced stages. It can also lead to abnormal
manifestations in other organs including bone, skin, retina, teeth
and other malignant lesions. FAP is a rare disease that affects 1
in 10,000 people with approximately 30,000 cases estimated in the
U.S.30 Of those diagnosed with FAP, approximately 70%
are diagnosed with inherited disease31, with the
remaining 30% diagnosed separately and likely at a later stage.
The FDA granted CPP-1X/sulindac its Orphan Drug Designation, as
well as its Fast Track designation, a process designed to
facilitate development and expedite the review of drugs to treat
serious conditions and fill an unmet medical need32.
Orphan Drug status was also granted to the therapy by the EMA.
A Phase 2 Proof of Concept trial in FAP and a Phase 2/3 trial in
high-risk polyp formers demonstrated the potential for
CPP-1X/sulindac in patients with FAP33. Current
therapeutic interventions are limited to endoscopies and
surgeries[34], which only decrease polyp burden in the
gastrointestinal tract and do not address other disease
manifestations. CPP-1X/sulindac, if approved, will target the
underlying disease mechanism, preventing polyp growth and delaying
disease progression.
Completion of the Phase 3 trial is currently expected at the end
of 2018. Assuming positive Phase 3 data, Mallinckrodt would acquire the exclusive option to
obtain North American commercial rights for a nominal fee, with CPP
retaining rights to the rest of the world. The NDA filing is
currently expected in early 2019, with approval also anticipated in
2019. Peak U.S. potential net sales for the product are estimated
at greater than $300 million. A part
of the profits from commercialization of CPP-1X/sulindac would be
shared with CPP.
"Both NPC and FAP are devastating conditions associated with
substantial morbidity and mortality, and effective therapies are
needed," said Steven Romano,
M.D., Chief Scientific Officer and Executive Vice President of
Mallinckrodt. "In addition to the
current patient benefits provided by AMITIZA, we look forward to
bringing VTS-270 and CPP-1X/sulindac to patients with critical
unmet medical needs."
Commercialization
If approved, Mallinckrodt expects to build on the limited
commercial infrastructure Sucampo has built for both VTS-270 and
CPP-1X/sulindac with its sales organizations currently focused on
rare diseases. At launch, patient access to these unique treatment
options would also be supported and enhanced by Mallinckrodt's strong relationships with insurance
companies and group purchasing organizations. Mallinckrodt's existing infrastructure of clinical
and medical affairs experts will also support approval and launch
of both products.
Financial Considerations and Closing
Sun Acquisition
Co., a subsidiary of Mallinckrodt, will
commence a cash tender offer to purchase all of the outstanding
shares of Sucampo Pharmaceuticals' common stock for $18.00 per share. The total transaction value
(including anticipated payments in respect of Sucampo's debt) is
approximately $1.2 billion. The
acquisition is expected to be funded through borrowings under
Mallinckrodt's existing revolving
credit facility, a new secured term loan facility and/or cash on
hand. Following the transaction, Mallinckrodt intends to utilize its significant
cash generation to focus on reducing outstanding debt over
time.
Sucampo stockholders holding approximately 32% of the
outstanding Sucampo shares have entered into a tender and support
agreement for this transaction.
Mallinckrodt expects accretion from
the acquisition to adjusted diluted earnings per share of at least
$0.30 in 2018 and at least double
that amount in 2019, assuming a first quarter 2018 close.
Guidance on the impact of the acquisition to the company's
GAAP35 diluted earnings per share has not been provided
due to the inherent difficulty of forecasting the timing or amount
of items that would be included in calculating such impact.
The transaction is subject to customary closing conditions,
including expiration of the applicable waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act, and the tender of a
majority of the outstanding Sucampo shares.
Advisors
Deutsche Bank served as Mallinckrodt's exclusive financial advisor;
Wachtell, Lipton, Rosen & Katz served as its exclusive legal
advisor. Jefferies LLC served as Sucampo's exclusive financial
advisor; Cooley LLP served as its exclusive legal advisor.
ABOUT SUCAMPO
Sucampo Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of highly specialized medicines. Sucampo has a
late-stage pipeline of product candidates in clinical development
for orphan disease areas, including VTS-270, a mixture of
2-hydroxypropyl-B-cyclodextrins with a specific compositional
fingerprint that has been granted orphan designation in the U.S.
and Europe and is in a pivotal
Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease
Type C, a rare progressive genetic disorder. VTS-270 has also been
granted breakthrough therapy designation in the U.S. Sucampo has an
exclusive option for the North American rights to CPP-1X/sulindac,
which is in Phase 3 development for the treatment of familial
adenomatous polyposis and has been granted orphan drug designation
in the U.S. The company has two marketed products – AMITIZA and
RESCULA. For more information, please visit www.sucampo.com.
ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops,
manufactures, markets and distributes specialty pharmaceutical
products and therapies. Areas of focus include autoimmune and rare
diseases in specialty areas like neurology, rheumatology,
nephrology, pulmonology and ophthalmology; immunotherapy and
neonatal respiratory critical care therapies; and analgesics and
hemostasis products. The company's core strengths include the
acquisition and management of highly regulated raw materials and
specialized chemistry, formulation and manufacturing capabilities.
The company's Specialty Brands segment includes branded medicines
and its Specialty Generics segment includes specialty generic
drugs, active pharmaceutical ingredients and external
manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission (SEC) disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
NON-GAAP FINANCIAL MEASURES
This press release
references adjusted diluted earnings per share, which is considered
a "non-GAAP" financial measure under applicable SEC rules and
regulations.
Adjusted diluted earnings per share represent adjusted net
income divided by the number of diluted shares. Adjusted net income
represents amounts, prepared in accordance with accounting
principles generally accepted in the U.S. (GAAP), adjusted for
certain items (on an after-tax basis) that management believes are
not reflective of the operational performance of the business.
Adjustments to GAAP amounts include restructuring and related
charges, net; amortization and impairment charges; discontinued
operations; acquisition-related expenses, changes in fair value of
contingent consideration obligations; inventory step-up expenses;
significant legal and environmental charges; pension settlement
charges; recurrent cash tax payments to the U.S. Internal Revenue
Service associated with internal installment sales transactions;
and other items identified by the company.
The company has provided these adjusted financial measures
because they are used by management, along with financial measures
in accordance with GAAP, to evaluate the company's operating
performance. In addition, the company believes that they will be
used by certain investors to measure Mallinckrodt's operating results. Management
believes that presenting these adjusted measures provides useful
information about the company's performance across reporting
periods on a consistent basis by excluding items that the company
does not believe are indicative of its core operating
performance.
These adjusted measures should be considered supplemental to and
not a substitute for financial information prepared in accordance
with GAAP. The company's definition of these adjusted measures may
differ from similarly titled measures used by others.
Because adjusted financial measures exclude the effect of items
that will increase or decrease the company's reported results of
operations, management strongly encourages investors to review the
company's consolidated financial statements and publicly filed
reports in their entirety.
Mallinckrodt Cautionary Statements Related to Forward-Looking
Statements
Statements in this document that are not strictly
historical, including statements regarding the proposed acquisition
of Sucampo Pharmaceuticals, the expected timetable for completing
the transaction, future financial condition and operating results,
benefits and synergies of the transaction, future opportunities for
the combined businesses and any other statements regarding events
or developments that the company believes or anticipates will or
may occur in the future, may be "forward-looking" statements within
the meaning of the federal securities laws, and involve a number of
risks and uncertainties.
There are a number of important factors that could cause actual
events to differ materially from those suggested or indicated by
such forward-looking statements and you should not place undue
reliance on any such forward-looking statements. These factors
include risks and uncertainties related to, among other things:
general economic conditions and conditions affecting the industries
in which Mallinckrodt and Sucampo
operate; the ability to obtain regulatory approval to market
Mallinckrodt's and Sucampo's products
or the timing of such approval processes; the commercial success of
Mallinckrodt's and Sucampo's products;
the parties' ability to satisfy the acquisition agreement
conditions and complete the Sucampo acquisition on the anticipated
timeline or at all; Mallinckrodt's
ability to realize anticipated growth, synergies and cost savings
from acquisitions (including the Sucampo acquisition); conditions
that could necessitate an evaluation of Mallinckrodt's goodwill and/or intangible assets
for possible impairment; changes in laws and regulations;
Mallinckrodt's ability to successfully
integrate acquisitions of operations, technology, products and
businesses generally and to realize anticipated growth, synergies
and cost savings (including with respect to the Sucampo
acquisition); Mallinckrodt's and
Mallinckrodt's licensers' ability to
successfully develop or commercialize new products; Mallinckrodt's and Mallinckrodt's licensers' ability to protect
intellectual property rights; Mallinckrodt's ability to receive procurement and
production quotas granted by the U.S. Drug Enforcement
Administration; customer concentration; Mallinckrodt's reliance on certain individual
products that are material to its financial performance; cost
containment efforts of customers, purchasing groups, third-party
payers and governmental organizations; the reimbursement practices
of a small number of public or private insurers; pricing pressure
on certain of Mallinckrodt's products
due to legal changes or changes in insurers' reimbursement
practices resulting from recent increased public scrutiny of
healthcare and pharmaceutical costs; limited clinical trial data
for H.P. Acthar® Gel; complex reporting and payment
obligations under healthcare rebate programs; Mallinckrodt's ability to navigate price
fluctuations; future changes to U.S. and foreign tax laws;
Mallinckrodt's ability to achieve
expected benefits from restructuring activities; complex
manufacturing processes; competition; product liability losses and
other litigation liability; ongoing governmental investigations;
material health, safety and environmental liabilities; retention of
key personnel; conducting business internationally; the
effectiveness of information technology infrastructure; and
cybersecurity and data leakage risks.
Additional information regarding the factors that may cause
actual results to differ materially from these forward-looking
statements is available in Mallinckrodt's SEC filings including its Annual
Report on Form 10-K for the fiscal year ended September 30, 2016, as well as such sections of
Ocera Therapeutic's Annual Report on Form 10-K for the fiscal year
ended December 31, 2016 and Sucampo's
SEC filings, including its Annual Report on Form 10-K for the
fiscal year ended December 31, 2016.
The forward-looking statements made herein speak only as of the
date hereof and none of Mallinckrodt,
Sucampo or any of their respective affiliates assumes any
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events and
developments or otherwise, except as required by law.
Sucampo Forward-Looking Statement
This press release
contains "forward-looking statements" as that term is defined in
the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and
involve risks and uncertainties, which may cause results to differ
materially from those set forth in the statements. The
forward-looking statements may include statements regarding
financial results, product development, and other statements that
are not historical facts. The following factors, among others,
could cause actual results to differ from those set forth in the
forward-looking statements: the impact of pharmaceutical industry
regulation and health care legislation; Sucampo's ability to
accurately predict future market conditions; Sucampo's ability to
successfully integrate the operations of acquired businesses;
dependence on the effectiveness of Sucampo's patents and other
protections for innovative products; the effects of competitive
products on Sucampo's products; and the exposure to litigation
and/or regulatory actions.
No forward-looking statement can be guaranteed and actual
results may differ materially from those projected. Sucampo
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk
factors and cautionary statements in Sucampo's most recent Form
10-K as filed with the Securities and Exchange Commission on
March 8, 2017, as well as its filings
with the Securities and Exchange Commission on Forms 8-K and 10-Q
since the filing of the Form 10-K, all of which Sucampo
incorporates by reference.
Additional Information and Notice to Investors
The
tender offer for the outstanding Sucampo shares referenced in this
document has not yet commenced. This document is for informational
purposes only and is neither an offer to purchase nor a
solicitation of an offer to sell shares, nor is it a substitute for
the tender offer materials that Mallinckrodt and Sun Acquisition Co. will file with
the SEC. At the time the tender offer is commenced, Mallinckrodt and Sun Acquisition Co. will file
tender offer materials on Schedule TO, and thereafter Sucampo will
file a Solicitation/Recommendation Statement on Schedule 14D-9 with
the SEC with respect to the tender offer. The tender offer
materials (including an offer to purchase, a related letter of
transmittal and certain other tender offer documents) and the
solicitation/recommendation statement will contain important
information. Holders of Sucampo's shares are urged to read these
documents carefully when they become available (as each may be
amended or supplemented from time to time) because they will
contain important information that holders of Sucampo's shares
should consider before making any decision regarding tendering
their shares. The Offer to Purchase, the related Letter of
Transmittal and certain other tender offer documents, as well as
the Solicitation/Recommendation Statement, will be made available
to all holders of Sucampo's shares at no expense to them. The
tender offer materials and the Solicitation/Recommendation
Statement will be made available for free at the SEC's website at
www.sec.gov. Copies of the documents filed by Mallinckrodt and Sun Acquisition Co. with the SEC
will also be available free of charge on the Investor Relations
section of its website at www.mallinckrodt.com and copies of the
documents filed by Sucampo with the SEC will be available free of
charge on Sucampo's website at www.sucampo.com. In addition to the
Offer to Purchase, the related Letter of Transmittal and certain
other tender offer documents, as well as the
Solicitation/Recommendation Statement, Sucampo and Mallinckrodt file annual, quarterly and current
reports and other information with the SEC. You may read and copy
any reports or other information filed by Sucampo or Mallinckrodt at the SEC public reference room at
100 F Street, N.E., Washington,
D.C. 20549. Please call the Commission at 1-800-SEC-0330 for
further information on the public reference room. Sucampo's and
Mallinckrodt's filings with the SEC are
also available to the public from commercial document-retrieval
services and at the SEC's website at www.sec.gov.
1 Prescription Drug User Fee Act
2 Internal estimates
3 Market defined by following brands: AMITIZA, Linzess®
(Allergan), Movantik® (AstraZeneca), Relistor® (Salix
Pharmaceuticals) and Trulance™ (Synergy Pharmaceuticals); reflects
2016 sales. Data from IQVIA (Previously known as IMS Health)
4 Loening-Baucke V. Prevalence rates for constipation
and faecal and urinary incontinence. Arch Dis Child. 2007
5 Vanier MC, et al. Orphanet J Rare Dis
2010;5(16):1-18.
6 Wassif CA, et al. Genet Med. 2016;18:41-48.
7 Maue RA, et al. Hum Mol Genet 2012;21(4):730-50.
8 Praggastis M, et al. J Neurosci
2015;35(21):8091-106.
9 Liu B, et al. J Lipid Res 2007;48(8):1710-23.
10 Orth M, Bellosta S. Cholesterol 2012;2012:292598.
11 Mauch DH, et al. Science 2001;294(5545):1354-7.
12 Saher G, et al. Nat Neurosci 2005;8(4):468-75.
13 Burlina A. J Neurol 2014;261:S525-S527.
14 Wraith JE, et al. Mol Genet Metab
2009;98:152-165.
15 Mengel E, et al. Mol Genet Metab 2017;120:180-9.
16 Vanier MT. J Inherit Metab Dis 2015:38:187.
17 Klunemann H, et al. Eur Neuro Rev 2011;12-15.
18 Imrie J et al. BMC Neurology 2015;15:257.
19 Ebrahimi-Fakhari D et al. Human Molecular Genetics.
25(16):3588-3599. 2016
20 Garver WS et al. Am J Med Genet A. 143A(11): 1204-11.
Jun 2007
21 Epidstat Analysis
22 ClearView Healthcare Partners Analys
23 Vtesse Analysis
24
https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/ucm329491.htm
25
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/RarePediatricDiseasePriorityVoucherProgram/default.htm
26 Davidson CD, et al. Ann Clin Transl Neurol
2016;3(5):366-80.
27 Liu B, et al. Proc Natl Acad Sci USA 2009;106(7):2377-82.
28 NIH Genetics Home Reference
29 Half E. et al. Orphanet Journal of Rare Diseases.
4:22. Oct 2009
30 National Organization for Rare Disorders
31 UptoDate. Kennedy RD, et al. J Pediatr Surg.
2014;49:82-86
32
https://www.fda.gov/forpatients/approvals/fast/ucm405399.htm
33 Meyskens FL, et al. Cancer Prev Res. 2008;1:32-38
34 Mount Sinai Zane Cohen Centre
35 Accounting principles generally accepted in the
U.S.
CONTACTS
Mallinckrodt plc
Investor
Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com
Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com
Sucampo Pharmaceuticals
Silvia
Taylor
Senior Vice President, Investor Relations and Corporate Affairs
240-223-3718
staylor@sucampo.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-acquire-sucampo-pharmaceuticals-for-approximately-12-billion-300575228.html
SOURCE Mallinckrodt plc